一氧化碳弥散功能在COPD评估中的作用
该研究基于COPDGene研究5年随访的1806例COPD患者,分析Dlco与症状、生活质量、运动能力和急性加重率的关系,并校正肺气肿和FEV1等混杂因素。多变量分析显示,Dlco每降低10%预计值,与CAT评分增加0.53、SGRQ评分增加1.67、SF-36生理功能评分降低0.89、6分钟步行距离减少45.35英尺及重度急性加重率比1.14独立相关。按Dlco和FEV1是否≤50%预计值分组后,单独Dlco严重受损、单独FEV1严重受损或两者均受损组,其各项预后指标均显著差于参考组。作者认为,未来COPD多维评估工具应考虑纳入Dlco。
要点
- 在COPD患者中,Dlco每降低10%预计值,与CAT评分增加0.53、SGRQ评分增加1.67独立相关(P < .001)。
- Dlco每降低10%预计值,与6分钟步行距离减少45.35英尺独立相关(P < .001)。
- Dlco每降低10%预计值,与重度急性加重率比1.14独立相关(P < .001)。
- 单独Dlco≤50%预计值或单独FEV1≤50%预计值,均与较参考组更差的症状、生活质量和运动能力显著相关(P < .05)。
- 即使校正CT肺气肿和FEV1后,Dlco受损仍与COPD疾病负担独立相关,作者建议未来多维评估工具考虑纳入Dlco。
适用人群与场景
- COPDGene研究中具有5年随访数据的1806例COPD参与者。
诊断标准与关键阈值
- Dlco和FEV1分组标准:参考组为Dlco和FEV1均>50%预计值;仅Dlco≤50%预计值组;仅FEV1≤50%预计值组;Dlco和FEV1均≤50%预计值组。
研究设计与关键结果
- 研究类型为基于COPDGene研究的分析,样本量1806例COPD参与者,分析其5年随访时的肺功能、生活质量、症状、运动能力和急性加重率。
- 多变量线性回归显示,Dlco每降低10%预计值,与CAT评分增加0.53(P < .001)、SGRQ评分增加1.67(P < .001)、SF-36生理功能评分降低0.89(P < .001)、6分钟步行距离减少45.35英尺(P < .001)独立相关。
- 多变量负二项回归显示,Dlco每降低10%预计值,与重度急性加重率比1.14(P < .001)独立相关。
- 与参考组相比,仅Dlco≤50%预计值组、仅FEV1≤50%预计值组以及两者均≤50%预计值组,在症状、生活质量、运动能力和重度急性加重方面均显著更差(所有结局P < .05)。
证据类型、等级与局限
- 证据类型:基于COPDGene研究的观察性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,Dlco受损与COPD症状增多、运动能力下降和重度急性加重风险升高相关,即使校正肺功能和CT肺气肿证据后仍存在。
- 作者建议,未来COPD多维评估工具应考虑纳入Dlco。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Diffusing capacity of the lung for carbon monoxide (Dlco) is inconsistently obtained in patients with COPD, and the added benefit of Dlco testing beyond that of more common tools is unknown.
OBJECTIVE: The goal of this study was to determine whether lower Dlco is associated with increased COPD morbidity independent of emphysema assessed via spirometry and CT imaging.
METHODS: Data for 1,806 participants with COPD from the Genetic Epidemiology of COPD (COPDGene) study 5-year visit were analyzed, including pulmonary function testing, quality of life, symptoms, exercise performance, and exacerbation rates. Dlco percent predicted was primarily analyzed as a continuous variable and additionally categorized into four groups: (1) Dlco and FEV1 > 50% (reference); (2) only Dlco ≤ 50%; (3) only FEV1 ≤ 50%; and (4) both ≤ 50% predicted. Outcomes were modeled by using multivariable linear and negative binomial regression, including emphysema and FEV1 percent predicted among other confounders.
RESULTS: In multivariable analyses, every 10% predicted decrease in Dlco was associated with symptoms and quality of life (COPD Assessment Test, 0.53 [P < .001]; St. George's Respiratory Questionnaire, 1.67 [P < .001]; Medical Outcomes Study Short Form 36 Physical Function, -0.89 [P < .001]), exercise performance (6-min walk distance, -45.35 feet; P < .001), and severe exacerbation rate (rate ratio, 1.14; P < .001). When categorized, severe impairment in Dlco alone, FEV1 alone, or both Dlco and FEV1 were associated with significantly worse morbidity compared with the reference group (P < .05 for all outcomes).
CONCLUSIONS: Impairment in Dlco was associated with increased COPD symptoms, reduced exercise performance, and severe exacerbation risk even after accounting for spirometry and CT evidence of emphysema. These findings suggest that Dlco should be considered for inclusion in future multidimensional tools assessing COPD.
参考来源
- Balasubramanian A, MacIntyre NR, Henderson RJ, et al. Diffusing Capacity of Carbon Monoxide in Assessment of COPD. Chest. 2019. PMID: 31352035. doi:10.1016/j.chest.2019.06.035
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。